Mmp activation peptide detection in biological samples
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsJan Johannes Enghild, Naftali Kaminski, Tim D. Oury, Laura Voeghtly
Life of this patent
Estimating the term…
Abstract
A method is provided along with related reagent kits for aiding the diagnosis of IPF or other interstitial lung diseases, as well as for potential monitoring of disease progression or therapeutic response to treatment.
Claims22
A method of identifying interstitial lung disease, monitoring interstitial lung disease progression, or determining effectiveness of treatment of an interstitial lung disease in a patient, comprising determining a level of one or more of MMP2 activation peptide, MMP7 activation peptide, MMP8 activation peptide and MMP9 activation peptide in urine of the patient, and identifying whether the patient has interstitial lung disease by determining if levels of one or more of MMP2 activation peptide, MMP7 activation peptide, MMP8 activation peptide and MMP9 activation peptide in urine of the patient exceed a threshold level indicative of interstitial lung disease.
A kit comprising binding reagents specific to MMP9 activation peptide, MMP7 activation peptide, and one or both of MMP2 activation peptide and MMP8 activation peptide and one or more detection reagents for detecting binding of the binding reagents to MMP9 activation peptide, MMP7 activation peptide, and one or both of MMP2 activation peptide and MMP8 activation peptide.
Dependencies are inferred from the claim text.